Phase 3 study of AJG533 in patients with chronic constipation

Efficacy and safety trial of AJG533 in patients with chronic constipation (Phase 3 study)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223008

Enrollment

120

Registered

2015-11-09

Start date

2015-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic constipation

Interventions

investigational material(s) Generic name etc : AJG533 INN of investigational material : elobixibat Therapeutic category code : 235 Purgatives and clysters Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic constipation

Exclusion criteria

Exclusion criteria: Patients with known or suspected organic constipation Patients with known or suspected symptomatic constipation or drug-induced constipation

Design outcomes

Primary

Measure	Time frame
Frequency of Spontaneous Bowel Movement Change from baseline	—

Secondary

Measure	Time frame
Complete Spontaneous Bowel Movement Rate of Patients Experienced the First SBM within 24 Hours/ 48 Hours SBM and CSBM Responder Rate Time to the First SBM Use of Rescue Medication Stool Consistency Measured by Bristol Stool Form Scale	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026